Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06651593 | Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors | PHASE2 | RECRUITING | 40 | — | — | Jul 2, 2025 | Sep 1, 2030 | May 6, 2026 | 1 | United States |
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
| Arm | Type | Description |
|---|---|---|
| Treatment with SAR444881 and Cemiplimab | EXPERIMENTAL | SAR444881 will be given by vein over about 60 minutes on Day 1 of each cycle. Cemiplimab will be administered by vein over about 30 minutes on Day 1 of each cycle, starting with Cycle 2. During Cycle 1, you will only receive SAR444881. Starting on Day 1 of Cycle 2 and for all other cycles, you will receive both SAR444881 and cemiplimab. |
| Name | Type | Description |
|---|---|---|
| SAR444881 | DRUG | Given by IV |
| Cemiplimab | DRUG | Given by Iv |
Inclusion Criteria: 1. Ability to understand and willingness to sign an informed consent form (ICF) prior to initiation of the study and any study procedures. 2. Age 18 years. 3. Participants with histologically documented locally advanced or metastatic solid tumor: * Cohort 1: NSCLC * Cohor...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |